Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners

5 - 6 June 2014, Paris, France.
Doctors 2.0 & You, partner of Stanford Medicine X and known for its 360° inclusive perspective on the patient, the physician, and digital tools, today announced 4th edition highlights. Remarking that "healthcare is now a recognized part of the explosion in social media, apps, quantified self and wearables," founder Denise Silber, confirms that "the June, 2014 program will provide an intensive look at the many moving parts of digital health and their results to date. How do patients and physicians benefit?"

Doctors 2.0 & You will bring attendees the latest insights and research on the ePatient and the digital doctor, individually and in communities, social media campaigns, eReputation, mobile apps, Serious Games and simulation, Quantified self and wearables including Google Glass and sensors. These tools will be envisaged from the standpoint of patients and physicians and other key stakeholders: pharma and device industries and suppliers, technology companies, payers, government. Participants originate from around the world and provide both a global and national perspective.

"So many people keep talking about digital, 2.0, social media... applied to the healthcare world. Doctors 2.0 & You helps make it happen, by spotting trends and talent and bringing la crème de la crème together. Doctors 2.0 & You is a best practice in Europe,” said Bernard Peyrical, Sanofi.

Some highlights from the 20 hours of activities including 22 parallel sessions and plenary, and 6 hours of Networking

  • Connected Objects, Quantified Self: Special activities around connected objects and quantified self will be developed for attendees thanks to the new Platinum Partnership with iHealthLabs Europe, founded by Uwe Diegel. Other quantified self players, ePatient and physician users, and pharma (Novartis) will provide their testimonials.
  • Google Glass: Four international pioneer Google Glass explorers will present exciting perspectives on health and medicine. Diversifying digital pharma
  • Pharma partners from hospitals and patient and physician communities will discuss relationships and results.
  • Dr Berci Mesko, founder of Webicina and medical futurist, will provide a limited seat Master Class on quality of web resources.
  • Award winning mobile apps and social media campaigns from Europe and the US will explain how they did it.
  • Three authors from the US, Hungary, and France will sign their books at the June 5th networking reception.
  • Stanford Medicine X and Doctors 2.0 & You will sponsor a medical student leader participant.
  • Announcement of the Doctors 2.0 & You Start Up Finalist who will fly to Palo Alto in September to present
  • Returning partners Novartis, Sanofi, LexisNexis and DocCheck will provide exciting activities in the exhibit hall.
  • Doctors 2.0 & You welcomes new supporting partners Ben's Friends and SOPE (Society of Physician Entrepreneurs).

For further information, please visit:
http://www.doctors20.com

About Doctors 2.0 & You
The Doctors 2.0TM & You conference series, organized by Basil Strategies, digital health consultancy (Paris), is the only international congress devoted to the understanding of how physicians use New Technologies, Web 2.0 tools and Social Media to communicate with colleagues, patients, payers, pharmaceutical companies and public agencies. The 4th edition will take place in Paris on June 5-6, 2014. The conference website and blog includes videos, past presentations, interviews, and other content.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Novartis teams up with Harvard to develop next gen…

Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Can...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...